Filtered By:
Source: Circulation
Condition: Diabetes Type 2

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 46 results found since Jan 2013.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
CONCLUSIONS: In this post hoc analysis of patients with type 2 diabetes mellitus and high cardiovascular risk, liraglutide reduced cardiovascular outcomes both in patients with a history of MI/stroke and in those with established atherosclerotic cardiovascular disease without MI/stroke. The cardiovascular effect appeared neutral in patients with cardiovascular risk factors alone. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01179048. PMID: 30566004 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Authors: Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP Tags: Circulation Source Type: research

Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes and Type 2 Diabetes: A Mendelian Randomization Analysis.
Conclusions -Both general and central adiposity have causal effects on CHD and T2D. Central adiposity may have a stronger effect on stroke risk. Future estimates of the burden of adiposity on health should include measures of central and general adiposity. PMID: 28500271 [PubMed - as supplied by publisher]
Source: Circulation - May 12, 2017 Category: Cardiology Authors: Dale C, Fatemifar G, Palmer T, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jefferis BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan Tags: Circulation Source Type: research

Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
Conclusions -Among patients with insulin resistance without diabetes, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MI's. Clinical Trial Registration - https://clinicaltrials.gov Unique Identifier: NCT00091949 US Food & Drug Administration IND: 64,622; EudraCT#2008-005546-23. PMID: 28246237 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Chronic Inflammatory Disorders and Risk of Type 2 Diabetes Mellitus, Coronary Heart Disease, and Stroke: A Population-Based Cohort Study.
CONCLUSIONS: -The risk of cardiovascular diseases and T2DM is increased across a range of organ-specific and multi-system chronic inflammatory disorders with evidence that risk is associated with severity of inflammation. Clinical management of patients with chronic inflammatory disorders should aim to reduce cardiovascular risk. PMID: 24970784 [PubMed - as supplied by publisher]
Source: Circulation - June 26, 2014 Category: Cardiology Authors: Dregan A, Charlton J, Chowienczyk P, Gulliford MC Tags: Circulation Source Type: research

Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
CONCLUSIONS: Among patients with type 2 diabetes and CAD in the BARI 2D trial, neither on-treatment nor propensity matched analysis supported an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT00006305. PMID: 23857320 [PubMed - as supplied by publisher]
Source: Circulation - July 15, 2013 Category: Cardiology Authors: Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber AJ, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL, for the BARI 2D Investigators Tags: Circulation Source Type: research

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial.
CONCLUSIONS: -Low-dose aspirin did not affect the risk for cardiovascular events, but increased risk for gastrointestinal bleeding in patients with type 2 diabetes in a primary prevention setting. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00110448. PMID: 27881565 [PubMed - as supplied by publisher]
Source: Circulation - November 14, 2016 Category: Cardiology Authors: Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, Morimoto T, JPAD Trial Investigators Tags: Circulation Source Type: research

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.
Conclusions -Serial assessment of hsTnI revealed a substantial proportion of patients with T2DM without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes based on risk. Clinical Trial Registration -https://clinicaltrials.gov Identifier: NCT00968708. PMID: 28246236 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA Tags: Circulation Source Type: research

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
CONCLUSIONS : Patients with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular outcomes compared with the primary prevention patients. Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups. Additional studies will provide further insights into the effects of canagliflozin in these patient populations. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754. PMID: 29133604 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group Tags: Circulation Source Type: research

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program.
Conclusions : The effect of canagliflozin on cardiovascular and renal outcomes was not modified by baseline level of kidney function in people with type 2 diabetes and a history or high risk of cardiovascular disease down to eGFR levels of 30 mL/min/1.73 m2 Reassessing current limitations on the use of canagliflozin in CKD may allow additional individuals to benefit from this therapy. Clinical Trial Registration : URL: https://clinicaltrials.gov. Unique identifiers: NCT01032629, NCT01989754. PMID: 29941478 [PubMed - as supplied by publisher]
Source: Circulation - June 25, 2018 Category: Cardiology Authors: Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V Tags: Circulation Source Type: research

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
CONCLUSIONS: Liraglutide added to standard of care reduced the risk for major cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus and chronic kidney disease. These results appear to apply across the chronic kidney disease spectrum enrolled. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT01179048. PMID: 30566006 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Authors: Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Tags: Circulation Source Type: research

Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
CONCLUSIONS: In a cohort of 12,156 patients with T2DM and high CV risk, metformin use was associated with lower rates of all-cause mortality, including after adjustment for clinical variables and biomarkers, but not lower rates of the composite endpoint of CV death, MI, or ischemic stroke. This association was most apparent in patients without prior HF or moderate to severe CKD. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01107886. PMID: 31362530 [PubMed - as supplied by publisher]
Source: Circulation - July 30, 2019 Category: Cardiology Authors: Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM, SAVOR-TIMI 53 Steering Committee and Investigators Tags: Circulation Source Type: research

Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
Conclusions: Risk of residual confounding cannot be fully excluded. Individual therapeutic agents within each class may have different magnitudes of effect. In this large real-world cohort of diabetic patients already on GLP-1RA, addition of SGLT2i - compared to addition of sulfonylurea - conferred greater cardiovascular benefit. The magnitude of the cardiovascular risk reduction was comparable to the benefit seen in cardiovascular outcome trials of SGLT2i versus placebo where baseline GLP-1RA use was minimal. PMID: 33302723 [PubMed - as supplied by publisher]
Source: Circulation - December 11, 2020 Category: Cardiology Authors: Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E Tags: Circulation Source Type: research

Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patient with Type 2 Diabetes: The ADVANCE Trial.
CONCLUSIONS: Visit-to-visit variability in SBP and maximum SBP were independent risk factors for macrovascular and microvascular complications in type 2 diabetes. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Unique Identifier: NCT00145925. PMID: 23926207 [PubMed - as supplied by publisher]
Source: Circulation - August 7, 2013 Category: Cardiology Authors: Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, Patel A, Neal B, Glasziou P, Hamet P, Mancia G, Poulter N, Williams B, Macmahon S, Chalmers J, on behalf of the ADVANCE Collaborative Group Tags: Circulation Source Type: research

Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial.
CONCLUSIONS: -In the context of balanced primary and secondary endpoints, saxagliptin treatment was associated with an increased risk for hospitalization for heart failure. This increase in risk was highest among patients with elevated levels of natriuretic peptides, prior heart failure, or chronic kidney disease. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT01107886. PMID: 25189213 [PubMed - as supplied by publisher]
Source: Circulation - September 4, 2014 Category: Cardiology Authors: Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, for the SAVOR-TIMI 53 Steering Committee and Investi Tags: Circulation Source Type: research

Bariatric Surgery: "Roux"-minating on Endothelial Cell and HDL Function.
Abstract Obesity, defined as a body mass index ≥ 30 kg/m2, is pandemic. Though prevalence in the United States has plateaued at ~31% of adults (78 million), worldwide obesity rates continue to rise(1). Perhaps more concerning is the high level of childhood obesity: 16.9% in US and ~13% (and rising) in developing countries(2). Why the alarm? Longitudinal studies of overweight or obese individuals have identified a 20 fold increase in risk for developing diabetes mellitus type 2 (T2D) and 1.5 fold increase risk for cardiovascular disease (CVD), including myocardial infarction, stroke and heart failure(3, 4). As ob...
Source: Circulation - February 11, 2015 Category: Cardiology Authors: Brown JD Tags: Circulation Source Type: research